Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Mar 20;353(9157):947-54.
doi: 10.1016/s0140-6736(98)06532-5.

Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial

E W Alton  1 , M Stern, R Farley, A Jaffe, S L Chadwick, J Phillips, J Davies, S N Smith, J Browning, M G Davies, M E Hodson, S R Durham, D Li, P K Jeffery, M Scallan, R Balfour, S J Eastman, S H Cheng, A E Smith, D Meeker, D M Geddes
Affiliations
Clinical Trial

Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial

E W Alton et al. Lancet. .

Abstract

Background: We and others have previously reported significant changes in chloride transport after cationic-lipid-mediated transfer of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to the nasal epithelium of patients with cystic fibrosis. We studied the safety and efficacy of this gene transfer to the lungs and nose of patients with cystic fibrosis in a double-blind placebo-controlled trial.

Methods: Eight patients with cystic fibrosis were randomly assigned DNA-lipid complex (active) by nebulisation into the lungs followed 1 week later by administration to the nose. Eight control patients followed the same protocol but with the lipid alone (placebo). Safety was assessed clinically, by radiography, by pulmonary function, by induced sputum, and by histological analysis. Efficacy was assessed by analysis of vector-specific CFTR DNA and mRNA, in-vivo potential difference, epifluorescence assay of chloride efflux, and bacterial adherence.

Findings: Seven of the eight patients receiving the active complex reported mild influenza-like symptoms that resolved within 36 h. Six of eight patients in both the active and placebo groups reported mild airway symptoms over a period of 12 h following pulmonary administration. No specific treatment was required for either event. Pulmonary administration resulted in a significant (p<0.05) degree of correction of the chloride abnormality in the patients receiving active treatment but not in those on placebo when assessed by in-vivo potential difference and chloride efflux. Bacterial adherence was also reduced. We detected no alterations in the sodium transport abnormality. A similar pattern occurred following nasal administration.

Interpretation: Cationic-lipid-mediated CFTR gene transfer can significantly influence the underlying chloride defect in the lungs of patients with cystic fibrosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Advances in cell and gene-based therapies for cystic fibrosis lung disease.
    Oakland M, Sinn PL, McCray PB Jr. Oakland M, et al. Mol Ther. 2012 Jun;20(6):1108-15. doi: 10.1038/mt.2012.32. Epub 2012 Feb 28. Mol Ther. 2012. PMID: 22371844 Free PMC article. Review.
  • Rapid identification of novel functional promoters for gene therapy.
    Pringle IA, Gill DR, Connolly MM, Lawton AE, Hewitt AM, Nunez-Alonso G, Cheng SH, Scheule RK, Davies LA, Hyde SC. Pringle IA, et al. J Mol Med (Berl). 2012 Dec;90(12):1487-96. doi: 10.1007/s00109-012-0928-6. Epub 2012 Jul 6. J Mol Med (Berl). 2012. PMID: 22767241
  • Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Alton EWFW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DDS, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JSR, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P; UK Cystic Fibrosis Gene Therapy Consortium. Alton EWFW, et al. Lancet Respir Med. 2015 Sep;3(9):684-691. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3. Lancet Respir Med. 2015. PMID: 26149841 Free PMC article. Clinical Trial.
  • Vectors for airway gene delivery.
    Davis PB, Cooper MJ. Davis PB, et al. AAPS J. 2007 Jan 19;9(1):E11-7. doi: 10.1208/aapsj0901002. AAPS J. 2007. PMID: 17408235 Free PMC article. Review.
  • Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli.
    Larsen MD, Griesenbach U, Goussard S, Gruenert DC, Geddes DM, Scheule RK, Cheng SH, Courvalin P, Grillot-Courvalin C, Alton EW. Larsen MD, et al. Gene Ther. 2008 Mar;15(6):434-42. doi: 10.1038/sj.gt.3303090. Epub 2008 Jan 24. Gene Ther. 2008. PMID: 18317498 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms